NCT00106704
Completed
Phase 3
A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Glimepiride Alone or in Combination With Metformin
ConditionsDiabetes Mellitus, Type 2
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Diabetes Mellitus, Type 2
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 441
- Primary Endpoint
- Change From Baseline in A1C at Week 24
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with Type 2 diabetes mellitus.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with Type 2 Diabetes Mellitus with inadequate glycemic control
Exclusion Criteria
- •Patients with Type 1 Diabetes Mellitus
Outcomes
Primary Outcomes
Change From Baseline in A1C at Week 24
Time Frame: Baseline and 24 Weeks
Hemoglobin A1C (A1C) is measured as percent. Thus this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.
Secondary Outcomes
- Change From Baseline in FPG at Week 24(Baseline and 24 Weeks)
Similar Trials
Completed
Phase 3
Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)GoutNCT00856206Regeneron Pharmaceuticals1,315
Completed
Phase 3
PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)GoutNCT00958438Regeneron Pharmaceuticals248
Completed
Phase 3
PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1Intercritical GoutNCT00829829Regeneron Pharmaceuticals241
Completed
Phase 3
Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)Diabetes Mellitus, Type 2NCT00087516Merck Sharp & Dohme LLC741
Completed
Phase 3
MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)Type 2 Diabetes MellitusNCT00289848Merck Sharp & Dohme LLC530